Summary

The global Pulmonary Drug Delivery and Inhalation Devices market is projected to grow from US$ 16574 million in 2025 to US$ 22179 million by 2032, at a CAGR of 4.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Pulmonary Drug Delivery and Inhalation Devices refer to medical drug-delivery systems designed to generate, meter, aerosolize, disperse, and deliver pharmaceutical formulations through the respiratory tract, primarily for deposition in the lungs and airways. The market covered in this study centers on Pressurized Metered-dose Inhalers, Dry Powder Inhalers, Nebulizers, and Soft Mist Inhalers, together with conventional mechanical and smart connected device configurations used in pulmonary therapy. Device performance depends on the interaction among formulation properties, aerosol generation mechanism, particle or droplet characteristics, metering accuracy, airflow resistance, patient inspiratory capability, and human-factor design. The FDA recognizes metered-dose and dry-powder inhalers as products that deliver drug substances through the inhalation route, while nebulization systems convert liquid formulations into respirable aerosols using pneumatic, ultrasonic, vibrating-mesh or related technologies. This study focuses on devices used across Homecare, Hospital & Clinic and other professional care settings, with major therapeutic applications in Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and other pulmonary disorders requiring localized or systemic inhaled drug delivery.
Key Findings
Pulmonary Drug Delivery and Inhalation Devices are structured around pMDIs, DPIs, Nebulizers and Soft Mist Inhalers
Asthma and COPD remain the principal application foundations, while CF and other pulmonary diseases support specialized inhalation demand
Smart Connected Inhalation Devices are shifting product differentiation toward adherence monitoring, dose tracking and inhalation-technique feedback
Low-GWP pMDI technology and portable vibrating-mesh nebulization are becoming important technology-upgrade directions
Market Trends
The Pulmonary Drug Delivery and Inhalation Devices industry is moving from basic aerosol generation toward patient-centric, environmentally sustainable and digitally supported drug delivery. Device selection is increasingly linked not only to the pharmaceutical formulation but also to the patient's inspiratory flow, hand-breath coordination, dexterity, age, cognitive capability and ability to use the device correctly. GINA emphasizes that inhaler selection should consider whether patients can correctly operate the device after training and notes that incorrect technique and poor adherence can materially affect asthma outcomes; electronic inhaler monitoring is also increasingly used to identify adherence problems. At the technology level, vibrating-mesh nebulizers are improving portability, treatment speed, quietness and aerosol control, while connected inhalers are adding usage sensing, dose monitoring, technique assessment and healthcare-data functions. Sustainability is becoming another structural innovation driver. The EU has incorporated metered-dose inhalers into its HFC quota framework, while the EMA has established requirements for transitioning pMDIs toward low-global-warming-potential propellants. GSK and AstraZeneca are among companies progressing lower-carbon or next-generation-propellant pMDI programs, indicating that environmental redesign is becoming part of inhaler lifecycle management rather than a peripheral product feature.
Market Dynamics
Drivers
Demand for Pulmonary Drug Delivery and Inhalation Devices is fundamentally supported by the long-term treatment requirements of asthma, COPD and other chronic respiratory diseases, where repeated inhaled administration creates recurring demand for reliable and patient-compatible drug-delivery platforms. Inhaled therapy can deliver medication directly to the respiratory tract, while device choice allows treatment to be adapted to patient capability and clinical setting. pMDIs and DPIs provide highly portable maintenance and rescue-treatment formats, whereas nebulizers can reduce the requirement for complex hand-breath coordination and therefore remain important for pediatric, elderly, debilitated and acute-care patients. Continued development of single-inhaler combination therapies, portable nebulization systems and home-based chronic disease management is further increasing the strategic importance of device usability, dose consistency and treatment convenience.
Restraints
The market is constrained by the close interdependence between drug formulation and device performance. Different inhaler types require different breathing techniques, and DPIs depend substantially on adequate inspiratory flow, while conventional pMDIs can require precise coordination between actuation and inhalation. Nebulizers simplify some aspects of administration but may introduce treatment-time, cleaning, maintenance and power-supply requirements. Development barriers are also higher than for conventional stand-alone medical devices because many inhaler products function as drug-device combination products and require extensive control of aerosol performance, metering accuracy, particle-size distribution, container-closure compatibility and manufacturing consistency. For pMDI manufacturers, transition toward new low-GWP propellants additionally requires formulation, material compatibility, performance and regulatory bridging work, increasing development complexity in the near term.
Opportunities
The principal opportunity lies in upgrading Pulmonary Drug Delivery and Inhalation Devices from passive administration tools into integrated therapeutic platforms. Smart Connected Inhalation Devices can record usage events, monitor remaining doses, evaluate inhalation technique and transmit information to digital health systems, creating opportunities in adherence management and remote chronic-disease monitoring. Advanced nebulization represents another opportunity, particularly vibrating-mesh and breath-triggered systems capable of improving portability, reducing treatment burden and supporting drug-specific aerosol delivery. PARI and other inhalation technology developers are increasingly working with pharmaceutical partners on customized nebulizer platforms, while Phillips Medisize has expanded its inhalation capabilities into small molecules, biologics, complex formulations, pMDIs, DPIs and nebulization following the integration of Vectura capabilities. This broadens the addressable opportunity from conventional respiratory medicines toward higher-value inhaled therapies requiring optimized formulation-device combinations.
Challenges
The long-term challenge is to simultaneously improve clinical performance, usability, sustainability and manufacturing economics without introducing additional patient complexity. Inhaler platforms must deliver reproducible doses under variable real-world inhalation conditions, while connected devices must add useful digital functionality without compromising reliability or creating excessive software, data-management and user-interface burdens. The coexistence of pMDIs, DPIs, Soft Mist Inhalers and multiple nebulizer technologies also means that patient training remains structurally important because operating techniques are not interchangeable. Manufacturers must also manage the transition to environmentally improved propellants while retaining equivalent aerosol and therapeutic performance, an issue that requires substantial formulation and device re-engineering. As competition shifts toward integrated drug-device solutions, the ability to combine pharmaceutical science, aerosol engineering, human factors, regulatory capabilities and scalable manufacturing becomes increasingly critical.
Industry Chain Analysis
The Pulmonary Drug Delivery and Inhalation Devices industry chain begins with pharmaceutical active ingredients and inhalation formulations, alongside device materials and components such as engineering plastics, metal canisters, elastomers, metering valves, actuators, powder reservoirs, capsules or blisters, compressors, vibrating-mesh elements, electronics, sensors and connectivity modules. In the midstream, inhalation-device developers integrate formulation characteristics with aerosol-generation and metering technologies to create pMDIs, DPIs, Nebulizers and Soft Mist Inhalers, followed by pharmaceutical filling, assembly, performance testing, combination-product validation and scaled manufacturing. FDA guidance highlights the importance of delivered particle-size distribution and aerosol performance, illustrating why formulation, container-closure system and delivery-device engineering must be developed as an integrated system. Downstream demand comes from pharmaceutical companies, hospitals and clinics, pharmacies, distributors and Homecare users. Value creation is therefore concentrated not simply in device manufacturing, but in reliable pulmonary deposition, accurate and repeatable dosing, drug-device compatibility, patient usability, regulatory evidence and manufacturability at commercial scale. Specialized suppliers such as Aptar Pharma and Phillips Medisize increasingly participate across multiple stages, from metering and device platforms through formulation support, development and manufacturing, reflecting a shift toward more integrated inhalation-development ecosystems.
Segment Insights
By Type, Pressurized Metered-dose Inhalers and Dry Powder Inhalers remain the core portable inhaler architectures for chronic respiratory treatment. pMDIs provide compact multidose delivery but require close control of formulation, propellant, valve, canister and actuator performance; the segment is now entering a significant technology transition toward low-GWP propellants. DPIs avoid propellants and can offer breath-actuated delivery, but their performance is more dependent on patient inspiratory flow and powder formulation characteristics. Soft Mist Inhalers occupy a differentiated position by mechanically generating a slow-moving aerosol mist, while Nebulizers remain particularly important where normal tidal breathing, liquid formulations or reduced coordination requirements are preferred.
Within Nebulizers, the technology mix is moving beyond conventional compressor-driven jet systems toward compact mesh-based platforms. OMRON distinguishes compressor nebulizers, which use compressed air, from mesh systems that use high-frequency vibration to force medication through fine apertures; Aerogen similarly uses vibrating-mesh technology to generate respirable droplets for acute-care and other pulmonary drug-delivery settings. By Intelligence, Conventional Inhalation Devices remain the installed base, while Smart Connected Inhalation Devices represent a higher-value development direction through dose counting, event recording, adherence assessment and technique feedback. Device intelligence is therefore becoming an additional segmentation dimension layered onto the traditional pMDI, DPI, nebulizer and soft-mist technology structure.
Downstream Market Opportunities
Asthma and Chronic Obstructive Pulmonary Disease (COPD) form the broadest recurring-use foundation for Pulmonary Drug Delivery and Inhalation Devices because both diseases rely extensively on inhaled maintenance and/or reliever therapies, and clinical guidelines emphasize correct inhaler selection, technique and adherence as integral components of treatment. Cystic Fibrosis (CF) represents an important specialized market for nebulized therapies, where aerosolized antibiotics and other inhaled treatments require efficient lung deposition and drug-specific delivery systems; PARI identifies CF as a major application area for its nebulization platforms. IPF and broader fibrotic or rare pulmonary diseases offer emerging opportunities as pharmaceutical developers investigate inhaled formulations intended to increase local pulmonary exposure while potentially reducing systemic exposure. PARI's current pharmaceutical-partner activities include development programs involving inhaled therapies for progressive pulmonary fibrosis, illustrating the extension of advanced inhalation technology beyond traditional obstructive respiratory diseases. From an End-user perspective, Homecare benefits from compact, battery-powered, quiet and easy-to-use platforms, while Hospital & Clinic demand emphasizes reliable aerosol delivery across acute, ventilated and non-ventilated respiratory care.
Regional Insights
North America and Europe are high-value mature markets for Pulmonary Drug Delivery and Inhalation Devices, characterized by broad use of combination inhaled therapies, established regulatory frameworks for drug-device combination products and active adoption of next-generation inhaler technologies. Europe is also becoming an important regulatory catalyst for sustainable pMDI redesign because the EU fluorinated-gas framework and EMA guidance are accelerating the transition toward lower-GWP propellants. North America remains important for advanced pharmaceutical inhaler launches, connected drug-delivery solutions and specialized respiratory devices, supported by a developed pharmaceutical and respiratory-care ecosystem. Asia-Pacific provides substantial expansion potential across both pharmaceutical inhalers and Homecare nebulization as access to chronic respiratory treatment increases and regional manufacturers expand portable compressor and mesh-nebulizer offerings. Competitive positioning therefore differs by region: developed markets place greater weight on combination therapy, digital adherence, sustainability and lifecycle management, while emerging markets continue to combine technology upgrading with affordability, distribution coverage and broader access to respiratory treatment.
Competitive Landscape Analysis
Competition in Pulmonary Drug Delivery and Inhalation Devices is multi-layered because the market combines pharmaceutical drug-device franchises, specialist inhalation-platform suppliers and respiratory medical-device manufacturers. GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis and other pharmaceutical companies compete primarily through proprietary inhaled medicines and integrated inhaler platforms; GSK's current respiratory portfolio includes Ellipta-based products and Ventolin, while AstraZeneca markets both pMDI and DPI respiratory products and is expanding single-inhaler combination therapy. Aptar Pharma competes further upstream through pMDI metering valves, DPIs, breath-actuated inhalers and connected-device technologies, while Phillips Medisize has strengthened its position in formulation, inhaler design and combination-product development following the 2025 integration of Vectura capabilities. In nebulization, PARI, Aerogen, OMRON, Yuwell and other respiratory-device manufacturers compete around aerosol efficiency, portability, treatment time, noise, usability and application-specific device design. The competitive focus is consequently shifting away from stand-alone hardware specifications toward integrated drug-device performance, patient experience, sustainability, digital functions, intellectual property and the ability to support pharmaceutical partners through development and commercialization.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Pulmonary Drug Delivery and Inhalation Devices market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
AstraZeneca
Aptar Pharma
Chiesi
Boehringer Ingelheim
Novartis
OMRON
Philips
Organon
PARI GmbH
Aerogen
Teva Pharmaceuticals
Phillips Medisize (Molex)
Drive DeVilbiss Healthcare
Monaghan Medical
Yuwell
BMC Medical
Folee
Beurer
Entie Medical
CONTEC
Feellife
Segment by Type
Pressurized Metered-dose Inhalers
Dry Powder Inhalers
Nebulizers
Soft Mist Inhalers
Segment by Intelligence
Conventional Inhalation Devices
Smart Connected Inhalation Devices
Segment by End-Users
Homecare
Hospital & Clinic
Others
Segment by Application
Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Cystic Fibrosis (CF)
Idiopathic Pulmonary Fibrosis (IPF)
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Pulmonary Drug Delivery and Inhalation Devices study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Pulmonary Drug Delivery and Inhalation Devices: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pulmonary Drug Delivery and Inhalation Devices Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Pressurized Metered-dose Inhalers
1.2.3 Dry Powder Inhalers
1.2.4 Nebulizers
1.2.5 Soft Mist Inhalers
1.3 Market Segmentation by Intelligence
1.3.1 Global Pulmonary Drug Delivery and Inhalation Devices Market Size by Intelligence, 2021 vs 2025 vs 2032
1.3.2 Conventional Inhalation Devices
1.3.3 Smart Connected Inhalation Devices
1.4 Market Segmentation by End-Users
1.4.1 Global Pulmonary Drug Delivery and Inhalation Devices Market Size by End-Users, 2021 vs 2025 vs 2032
1.4.2 Homecare
1.4.3 Hospital & Clinic
1.4.4 Others
1.5 Market Segmentation by Application
1.5.1 Global Pulmonary Drug Delivery and Inhalation Devices Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Asthma
1.5.3 Chronic Obstructive Pulmonary Disease (COPD)
1.5.4 Cystic Fibrosis (CF)
1.5.5 Idiopathic Pulmonary Fibrosis (IPF)
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Pulmonary Drug Delivery and Inhalation Devices Revenue Estimates and Forecasts (2021-2032)
2.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Pulmonary Drug Delivery and Inhalation Devices Sales Estimates and Forecasts (2021-2032)
2.4 Global Pulmonary Drug Delivery and Inhalation Devices Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Pulmonary Drug Delivery and Inhalation Devices Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Pressurized Metered-dose Inhalers: Market Share by Key Manufacturers
3.5.2 Dry Powder Inhalers: Market Share by Key Manufacturers
3.5.3 Nebulizers: Market Share by Key Manufacturers
3.5.4 Soft Mist Inhalers: Market Share by Key Manufacturers
3.6 Global Pulmonary Drug Delivery and Inhalation Devices Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Performance by Type
4.1.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Type (2021-2032)
4.1.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Pulmonary Drug Delivery and Inhalation Devices Sales Performance by Intelligence
4.2.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Intelligence (2021-2032)
4.2.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Intelligence (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Intelligence (2021-2032)
4.3 Global Pulmonary Drug Delivery and Inhalation Devices Sales Performance by End-Users
4.3.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by End-Users (2021-2032)
4.3.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by End-Users (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by End-Users (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Pulmonary Drug Delivery and Inhalation Devices Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Pulmonary Drug Delivery and Inhalation Devices Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Pulmonary Drug Delivery and Inhalation Devices Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Pulmonary Drug Delivery and Inhalation Devices Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Pulmonary Drug Delivery and Inhalation Devices Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Pulmonary Drug Delivery and Inhalation Devices Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Pulmonary Drug Delivery and Inhalation Devices Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.1.4 GSK Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 GSK Pulmonary Drug Delivery and Inhalation Devices Sales by Product in 2025
11.1.6 GSK Pulmonary Drug Delivery and Inhalation Devices Sales by Application in 2025
11.1.7 GSK Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Area in 2025
11.1.8 GSK Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
11.1.9 GSK Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.2.4 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales by Product in 2025
11.2.6 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales by Application in 2025
11.2.7 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Area in 2025
11.2.8 AstraZeneca Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
11.2.9 AstraZeneca Recent Developments
11.3 Aptar Pharma
11.3.1 Aptar Pharma Corporation Information
11.3.2 Aptar Pharma Business Overview
11.3.3 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.3.4 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales by Product in 2025
11.3.6 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales by Application in 2025
11.3.7 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Area in 2025
11.3.8 Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
11.3.9 Aptar Pharma Recent Developments
11.4 Chiesi
11.4.1 Chiesi Corporation Information
11.4.2 Chiesi Business Overview
11.4.3 Chiesi Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.4.4 Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales by Product in 2025
11.4.6 Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales by Application in 2025
11.4.7 Chiesi Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Area in 2025
11.4.8 Chiesi Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
11.4.9 Chiesi Recent Developments
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Corporation Information
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.5.4 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales by Product in 2025
11.5.6 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales by Application in 2025
11.5.7 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices Sales by Geographic Area in 2025
11.5.8 Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
11.5.9 Boehringer Ingelheim Recent Developments
11.6 Novartis
11.6.1 Novartis Corporation Information
11.6.2 Novartis Business Overview
11.6.3 Novartis Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.6.4 Novartis Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Novartis Recent Developments
11.7 OMRON
11.7.1 OMRON Corporation Information
11.7.2 OMRON Business Overview
11.7.3 OMRON Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.7.4 OMRON Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 OMRON Recent Developments
11.8 Philips
11.8.1 Philips Corporation Information
11.8.2 Philips Business Overview
11.8.3 Philips Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.8.4 Philips Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Philips Recent Developments
11.9 Organon
11.9.1 Organon Corporation Information
11.9.2 Organon Business Overview
11.9.3 Organon Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.9.4 Organon Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Organon Recent Developments
11.10 PARI GmbH
11.10.1 PARI GmbH Corporation Information
11.10.2 PARI GmbH Business Overview
11.10.3 PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.10.4 PARI GmbH Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 PARI GmbH Recent Developments
11.11 Aerogen
11.11.1 Aerogen Corporation Information
11.11.2 Aerogen Business Overview
11.11.3 Aerogen Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.11.4 Aerogen Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Aerogen Recent Developments
11.12 Teva Pharmaceuticals
11.12.1 Teva Pharmaceuticals Corporation Information
11.12.2 Teva Pharmaceuticals Business Overview
11.12.3 Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.12.4 Teva Pharmaceuticals Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Teva Pharmaceuticals Recent Developments
11.13 Phillips Medisize (Molex)
11.13.1 Phillips Medisize (Molex) Corporation Information
11.13.2 Phillips Medisize (Molex) Business Overview
11.13.3 Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.13.4 Phillips Medisize (Molex) Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Phillips Medisize (Molex) Recent Developments
11.14 Drive DeVilbiss Healthcare
11.14.1 Drive DeVilbiss Healthcare Corporation Information
11.14.2 Drive DeVilbiss Healthcare Business Overview
11.14.3 Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.14.4 Drive DeVilbiss Healthcare Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Drive DeVilbiss Healthcare Recent Developments
11.15 Monaghan Medical
11.15.1 Monaghan Medical Corporation Information
11.15.2 Monaghan Medical Business Overview
11.15.3 Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.15.4 Monaghan Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Monaghan Medical Recent Developments
11.16 Yuwell
11.16.1 Yuwell Corporation Information
11.16.2 Yuwell Business Overview
11.16.3 Yuwell Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.16.4 Yuwell Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Yuwell Recent Developments
11.17 BMC Medical
11.17.1 BMC Medical Corporation Information
11.17.2 BMC Medical Business Overview
11.17.3 BMC Medical Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.17.4 BMC Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 BMC Medical Recent Developments
11.18 Folee
11.18.1 Folee Corporation Information
11.18.2 Folee Business Overview
11.18.3 Folee Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.18.4 Folee Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Folee Recent Developments
11.19 Beurer
11.19.1 Beurer Corporation Information
11.19.2 Beurer Business Overview
11.19.3 Beurer Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.19.4 Beurer Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Beurer Recent Developments
11.20 Entie Medical
11.20.1 Entie Medical Corporation Information
11.20.2 Entie Medical Business Overview
11.20.3 Entie Medical Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.20.4 Entie Medical Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Entie Medical Recent Developments
11.21 CONTEC
11.21.1 CONTEC Corporation Information
11.21.2 CONTEC Business Overview
11.21.3 CONTEC Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.21.4 CONTEC Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 CONTEC Recent Developments
11.22 Feellife
11.22.1 Feellife Corporation Information
11.22.2 Feellife Business Overview
11.22.3 Feellife Pulmonary Drug Delivery and Inhalation Devices Product Models, Descriptions and Specifications
11.22.4 Feellife Pulmonary Drug Delivery and Inhalation Devices Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Feellife Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Pulmonary Drug Delivery and Inhalation Devices Industry Chain
12.2 Pulmonary Drug Delivery and Inhalation Devices Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Pulmonary Drug Delivery and Inhalation Devices Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Pulmonary Drug Delivery and Inhalation Devices Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Pulmonary Drug Delivery and Inhalation Devices Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Pulmonary Drug Delivery and Inhalation Devices Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Intelligence, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by End-Users, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Region (US$ Million), 2021-2026
Table 7. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Region (US$ Million), 2027-2032
Table 8. Global Pulmonary Drug Delivery and Inhalation Devices Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 9. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Region (K Units), 2021-2026
Table 10. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Region (K Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Manufacturers (K Units), 2021-2026
Table 13. Global Pulmonary Drug Delivery and Inhalation Devices Sales Share by Manufacturers (2021-2026)
Table 14. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Pulmonary Drug Delivery and Inhalation Devices Revenue, 2025
Table 18. Global Pulmonary Drug Delivery and Inhalation Devices Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Pulmonary Drug Delivery and Inhalation Devices Average Selling Price (ASP) by Manufacturers (K US$/Unit), 2021-2026
Table 20. Key Manufacturers Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base and Headquarters
Table 21. Global Pulmonary Drug Delivery and Inhalation Devices Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Type (K Units), 2021-2026
Table 25. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Type (K Units), 2027-2032
Table 26. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Type (US$ Million), 2021-2026
Table 27. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Type (US$ Million), 2027-2032
Table 28. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Intelligence (K Units), 2021-2026
Table 29. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by Intelligence (K Units), 2027-2032
Table 30. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Intelligence (US$ Million), 2021-2026
Table 31. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Intelligence (US$ Million), 2027-2032
Table 32. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by End-Users (K Units), 2021-2026
Table 33. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume by End-Users (K Units), 2027-2032
Table 34. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by End-Users (US$ Million), 2021-2026
Table 35. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by End-Users (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Application (K Units), 2021-2026
Table 38. Global Pulmonary Drug Delivery and Inhalation Devices Sales by Application (K Units), 2027-2032
Table 39. Pulmonary Drug Delivery and Inhalation Devices High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Application (US$ Million), 2021-2026
Table 41. Global Pulmonary Drug Delivery and Inhalation Devices Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Pulmonary Drug Delivery and Inhalation Devices Growth Accelerators and Market Barriers
Table 45. North America Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Pulmonary Drug Delivery and Inhalation Devices Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Pulmonary Drug Delivery and Inhalation Devices Growth Accelerators and Market Barriers
Table 48. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Pulmonary Drug Delivery and Inhalation Devices Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Growth Accelerators and Market Barriers
Table 53. Southeast Asia Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Pulmonary Drug Delivery and Inhalation Devices Investment Opportunities and Key Challenges
Table 55. Central and South America Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. GSK Corporation Information
Table 59. GSK Description and Major Businesses
Table 60. GSK Product Models, Descriptions and Specifications
Table 61. GSK Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 62. GSK Sales Value Proportion by Product in 2025
Table 63. GSK Sales Value Proportion by Application in 2025
Table 64. GSK Sales Value Proportion by Geographic Area in 2025
Table 65. GSK Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
Table 66. GSK Recent Developments
Table 67. AstraZeneca Corporation Information
Table 68. AstraZeneca Description and Major Businesses
Table 69. AstraZeneca Product Models, Descriptions and Specifications
Table 70. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 71. AstraZeneca Sales Value Proportion by Product in 2025
Table 72. AstraZeneca Sales Value Proportion by Application in 2025
Table 73. AstraZeneca Sales Value Proportion by Geographic Area in 2025
Table 74. AstraZeneca Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
Table 75. AstraZeneca Recent Developments
Table 76. Aptar Pharma Corporation Information
Table 77. Aptar Pharma Description and Major Businesses
Table 78. Aptar Pharma Product Models, Descriptions and Specifications
Table 79. Aptar Pharma Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 80. Aptar Pharma Sales Value Proportion by Product in 2025
Table 81. Aptar Pharma Sales Value Proportion by Application in 2025
Table 82. Aptar Pharma Sales Value Proportion by Geographic Area in 2025
Table 83. Aptar Pharma Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
Table 84. Aptar Pharma Recent Developments
Table 85. Chiesi Corporation Information
Table 86. Chiesi Description and Major Businesses
Table 87. Chiesi Product Models, Descriptions and Specifications
Table 88. Chiesi Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 89. Chiesi Sales Value Proportion by Product in 2025
Table 90. Chiesi Sales Value Proportion by Application in 2025
Table 91. Chiesi Sales Value Proportion by Geographic Area in 2025
Table 92. Chiesi Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
Table 93. Chiesi Recent Developments
Table 94. Boehringer Ingelheim Corporation Information
Table 95. Boehringer Ingelheim Description and Major Businesses
Table 96. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 97. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 98. Boehringer Ingelheim Sales Value Proportion by Product in 2025
Table 99. Boehringer Ingelheim Sales Value Proportion by Application in 2025
Table 100. Boehringer Ingelheim Sales Value Proportion by Geographic Area in 2025
Table 101. Boehringer Ingelheim Pulmonary Drug Delivery and Inhalation Devices SWOT Analysis
Table 102. Boehringer Ingelheim Recent Developments
Table 103. Novartis Corporation Information
Table 104. Novartis Description and Major Businesses
Table 105. Novartis Product Models, Descriptions and Specifications
Table 106. Novartis Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 107. Novartis Recent Developments
Table 108. OMRON Corporation Information
Table 109. OMRON Description and Major Businesses
Table 110. OMRON Product Models, Descriptions and Specifications
Table 111. OMRON Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 112. OMRON Recent Developments
Table 113. Philips Corporation Information
Table 114. Philips Description and Major Businesses
Table 115. Philips Product Models, Descriptions and Specifications
Table 116. Philips Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 117. Philips Recent Developments
Table 118. Organon Corporation Information
Table 119. Organon Description and Major Businesses
Table 120. Organon Product Models, Descriptions and Specifications
Table 121. Organon Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 122. Organon Recent Developments
Table 123. PARI GmbH Corporation Information
Table 124. PARI GmbH Description and Major Businesses
Table 125. PARI GmbH Product Models, Descriptions and Specifications
Table 126. PARI GmbH Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 127. PARI GmbH Recent Developments
Table 128. Aerogen Corporation Information
Table 129. Aerogen Description and Major Businesses
Table 130. Aerogen Product Models, Descriptions and Specifications
Table 131. Aerogen Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 132. Aerogen Recent Developments
Table 133. Teva Pharmaceuticals Corporation Information
Table 134. Teva Pharmaceuticals Description and Major Businesses
Table 135. Teva Pharmaceuticals Product Models, Descriptions and Specifications
Table 136. Teva Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 137. Teva Pharmaceuticals Recent Developments
Table 138. Phillips Medisize (Molex) Corporation Information
Table 139. Phillips Medisize (Molex) Description and Major Businesses
Table 140. Phillips Medisize (Molex) Product Models, Descriptions and Specifications
Table 141. Phillips Medisize (Molex) Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 142. Phillips Medisize (Molex) Recent Developments
Table 143. Drive DeVilbiss Healthcare Corporation Information
Table 144. Drive DeVilbiss Healthcare Description and Major Businesses
Table 145. Drive DeVilbiss Healthcare Product Models, Descriptions and Specifications
Table 146. Drive DeVilbiss Healthcare Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 147. Drive DeVilbiss Healthcare Recent Developments
Table 148. Monaghan Medical Corporation Information
Table 149. Monaghan Medical Description and Major Businesses
Table 150. Monaghan Medical Product Models, Descriptions and Specifications
Table 151. Monaghan Medical Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 152. Monaghan Medical Recent Developments
Table 153. Yuwell Corporation Information
Table 154. Yuwell Description and Major Businesses
Table 155. Yuwell Product Models, Descriptions and Specifications
Table 156. Yuwell Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 157. Yuwell Recent Developments
Table 158. BMC Medical Corporation Information
Table 159. BMC Medical Description and Major Businesses
Table 160. BMC Medical Product Models, Descriptions and Specifications
Table 161. BMC Medical Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 162. BMC Medical Recent Developments
Table 163. Folee Corporation Information
Table 164. Folee Description and Major Businesses
Table 165. Folee Product Models, Descriptions and Specifications
Table 166. Folee Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 167. Folee Recent Developments
Table 168. Beurer Corporation Information
Table 169. Beurer Description and Major Businesses
Table 170. Beurer Product Models, Descriptions and Specifications
Table 171. Beurer Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 172. Beurer Recent Developments
Table 173. Entie Medical Corporation Information
Table 174. Entie Medical Description and Major Businesses
Table 175. Entie Medical Product Models, Descriptions and Specifications
Table 176. Entie Medical Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 177. Entie Medical Recent Developments
Table 178. CONTEC Corporation Information
Table 179. CONTEC Description and Major Businesses
Table 180. CONTEC Product Models, Descriptions and Specifications
Table 181. CONTEC Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 182. CONTEC Recent Developments
Table 183. Feellife Corporation Information
Table 184. Feellife Description and Major Businesses
Table 185. Feellife Product Models, Descriptions and Specifications
Table 186. Feellife Sales (K Units), Revenue (US$ Million), Price (K US$/Unit) and Gross Margin (2021-2026)
Table 187. Feellife Recent Developments
Table 188. Key Raw Materials Distribution
Table 189. Raw Materials Key Suppliers
Table 190. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 191. Milestones in Production Technology Evolution
Table 192. Distributors List
Table 193. Market Trends and Market Evolution
Table 194. Market Drivers and Opportunities
Table 195. Market Challenges, Risks, and Restraints
Table 196. Research Programs/Design for This Report
Table 197. Key Data Information from Secondary Sources
Table 198. Key Data Information from Primary Sources

List of Figures
Figure 1. Pulmonary Drug Delivery and Inhalation Devices Product Picture
Figure 2. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Pressurized Metered-dose Inhalers Product Picture
Figure 4. Dry Powder Inhalers Product Picture
Figure 5. Nebulizers Product Picture
Figure 6. Soft Mist Inhalers Product Picture
Figure 7. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Intelligence, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. Conventional Inhalation Devices Product Picture
Figure 9. Smart Connected Inhalation Devices Product Picture
Figure 10. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by End-Users, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Homecare Product Picture
Figure 12. Hospital & Clinic Product Picture
Figure 13. Others Product Picture
Figure 14. Global Pulmonary Drug Delivery and Inhalation Devices Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Asthma
Figure 16. Chronic Obstructive Pulmonary Disease (COPD)
Figure 17. Cystic Fibrosis (CF)
Figure 18. Idiopathic Pulmonary Fibrosis (IPF)
Figure 19. Others
Figure 20. Pulmonary Drug Delivery and Inhalation Devices Report Years Considered
Figure 21. Global Pulmonary Drug Delivery and Inhalation Devices Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 23. Global Pulmonary Drug Delivery and Inhalation Devices Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global Pulmonary Drug Delivery and Inhalation Devices Sales (K Units), 2021-2032
Figure 26. Global Pulmonary Drug Delivery and Inhalation Devices Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 27. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Region (2021-2032)
Figure 28. Top 5 and Top 10 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Volume Market Share in 2025
Figure 29. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Pressurized Metered-dose Inhalers Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Dry Powder Inhalers Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Nebulizers Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Soft Mist Inhalers Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume-Based Market Share by Type (2021-2032)
Figure 36. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by Type (2021-2032)
Figure 37. Global Pulmonary Drug Delivery and Inhalation Devices ASP by Type (K US$/Unit), 2021-2032
Figure 38. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume-Based Market Share by Intelligence (2021-2032)
Figure 39. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by Intelligence (2021-2032)
Figure 40. Global Pulmonary Drug Delivery and Inhalation Devices ASP by Intelligence (K US$/Unit), 2021-2032
Figure 41. Global Pulmonary Drug Delivery and Inhalation Devices Sales Volume-Based Market Share by End-Users (2021-2032)
Figure 42. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by End-Users (2021-2032)
Figure 43. Global Pulmonary Drug Delivery and Inhalation Devices ASP by End-Users (K US$/Unit), 2021-2032
Figure 44. Global Pulmonary Drug Delivery and Inhalation Devices Sales Market Share by Application (2021-2032)
Figure 45. Global Pulmonary Drug Delivery and Inhalation Devices Revenue-Based Market Share by Application (2021-2032)
Figure 46. Global Pulmonary Drug Delivery and Inhalation Devices ASP by Application (K US$/Unit), 2021-2032
Figure 47. North America Pulmonary Drug Delivery and Inhalation Devices Sales YoY (K Units), 2021-2032
Figure 48. North America Pulmonary Drug Delivery and Inhalation Devices Revenue YoY (US$ Million), 2021-2032
Figure 49. North America Top 5 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) in 2025
Figure 50. North America Pulmonary Drug Delivery and Inhalation Devices Sales Volume (K Units) by Application (2021-2032)
Figure 51. North America Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) by Application (2021-2032)
Figure 52. US Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 53. Canada Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 54. Mexico Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 55. Europe Pulmonary Drug Delivery and Inhalation Devices Sales YoY (K Units), 2021-2032
Figure 56. Europe Pulmonary Drug Delivery and Inhalation Devices Revenue YoY (US$ Million), 2021-2032
Figure 57. Europe Top 5 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) in 2025
Figure 58. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Volume (K Units) by Application (2021-2032)
Figure 59. Europe Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) by Application (2021-2032)
Figure 60. Germany Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 61. France Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 62. U.K. Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 63. Italy Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 64. Russia Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 65. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Sales YoY (K Units), 2021-2032
Figure 66. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Revenue YoY (US$ Million), 2021-2032
Figure 67. Asia-Pacific Top 8 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) in 2025
Figure 68. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Sales Volume (K Units) by Application (2021-2032)
Figure 69. Asia-Pacific Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) by Application (2021-2032)
Figure 70. Indonesia Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 71. Japan Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 72. South Korea Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 73. China Taiwan Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 74. India Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 75. Central and South America Pulmonary Drug Delivery and Inhalation Devices Sales YoY (K Units), 2021-2032
Figure 76. Central and South America Pulmonary Drug Delivery and Inhalation Devices Revenue YoY (US$ Million), 2021-2032
Figure 77. Central and South America Top 5 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) in 2025
Figure 78. Central and South America Pulmonary Drug Delivery and Inhalation Devices Sales Volume (K Units) by Application (2021-2032)
Figure 79. Central and South America Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) by Application (2021-2032)
Figure 80. Brazil Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 81. Argentina Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 82. Middle East, and Africa Pulmonary Drug Delivery and Inhalation Devices Sales YoY (K Units), 2021-2032
Figure 83. Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Revenue YoY (US$ Million), 2021-2032
Figure 84. Middle East and Africa Top 5 Manufacturers Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) in 2025
Figure 85. Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Sales Volume (K Units) by Application (2021-2032)
Figure 86. Middle East and Africa Pulmonary Drug Delivery and Inhalation Devices Sales Revenue (US$ Million) by Application (2021-2032)
Figure 87. GCC Countries Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 88. Turkey Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 89. Egypt Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 90. South Africa Pulmonary Drug Delivery and Inhalation Devices Revenue (US$ Million), 2021-2032
Figure 91. Pulmonary Drug Delivery and Inhalation Devices Industry Chain Mapping
Figure 92. Regional Pulmonary Drug Delivery and Inhalation Devices Manufacturing Base Distribution (%)
Figure 93. Global Pulmonary Drug Delivery and Inhalation Devices Production Market Share by Region (2021-2032)
Figure 94. Pulmonary Drug Delivery and Inhalation Devices Production Process
Figure 95. Regional Pulmonary Drug Delivery and Inhalation Devices Production Cost Structure
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed